Brief: Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026
08/09/2026 12:47
BRIEF-Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 Sept 8 (Reuters) - Artiva Biotherapeutics Inc ARTV.O:
ARTIVA BIOTHERAPEUTICS PROVIDES UPDATE ON PLANNED ALLONK® DATA DISCLOSURES AND DEVELOPMENT MILESTONES FOR THE REMAINDER OF 2026
ARTIVA BIOTHERAPEUTICS - TO DISCLOSE UPDATED PHASE 2A RA DATA FROM AT LEAST 20 PATIENTS IN H2 2026
ARTIVA BIOTHERAPEUTICS - EXPECTS PHASE 3 RA TRIAL TOPLINE RESULTS BY END OF 2028
Source text: ID:nGNX9h5TQD
Further company coverage: ARTV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Artiva Biotherapeutics
See all newsBrief: Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026
Artiva Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Artiva Biotherapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Artiva Biotherapeutics Inc Thad Huston To Separate As CFO Effective May 22, 2026
U.S. STOCKS ON THE MOVE-Corning, BILL Holdings, Moderna